Panelists discuss how fitness assessment has evolved beyond traditional age cutoffs to incorporate comprehensive geriatric assessments, frailty measures, and individualized evaluations, while ...

Moleculin Biotech ( (MBRX)) just unveiled an announcement. Moleculin Biotech has revealed promising findings showcasing Annamycin’s potential to combat acute myeloid leukemia (AML) resistant to ...

Panelists discuss how social determinants of health significantly impact AML care, particularly regarding transportation access, health literacy, and the intensive nature of treatment requiring ...

The annual incidence of treatment-related acute myeloid leukemia has increased, in addition to an increase in the distribution of primary cancers.

Menin inhibitors reshape AML care, boosting targeted options for KMT2A- and NPM1-mutant disease, with promising frontline combinations beyond relapsed settings. In an interview with Targeted Oncology, ...

Sellas will present new data on its CDK9 inhibitor SLS009 at the American Association for Cancer Research (AACR) meeting on April 21. ・Preclinical findings showed SLS009 triggered leukemia cell death ...

Study from Japan shows near-tripling over 30-year period ...

Immunotherapy has revolutionized the way physicians treat patients with cancer. This form of cancer treatment aims to direct the immune system toward the rapidly growing tumor. As cancer progresses, ...

Relapsed acute myeloid leukemia (AML) is when cancer returns after a period of remission. Refractory AML means cancer has not responded to multiple rounds of treatment. Both can affect your treatment ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Moleculin Biotech ( (MBRX)) has ...